BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28210079)

  • 41. Serum Interleukin-33 level in Saudi children with inflammatory bowel disease.
    Saadah OI; Al-Harthi SE; Al-Mughales JA; Bin-Taleb YY; Baeshen RS
    Int J Clin Exp Pathol; 2015; 8(12):16000-6. PubMed ID: 26884875
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-Saccharomyces cerevisiae antibody titers are stable over time in Crohn's patients and are not inducible in murine models of colitis.
    Müller S; Styner M; Seibold-Schmid B; Flogerzi B; Mähler M; Konrad A; Seibold F
    World J Gastroenterol; 2005 Nov; 11(44):6988-94. PubMed ID: 16437604
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease.
    Zhang S; Wu Z; Luo J; Ding X; Hu C; Li P; Deng C; Zhang F; Qian J; Li Y
    Medicine (Baltimore); 2015 Oct; 94(42):e1654. PubMed ID: 26496271
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Inflammatory bowel disease in children--an analysis of the clinical symptoms and selected biochemical parameters].
    Landowski P; Liberek A; Szlagatys-Sidorkiewicz A; Radys W; Brodzicki J; Szarszewski A; Marek A; Łuczak G; Kamińska B
    Med Wieku Rozwoj; 2007; 11(4):401-7. PubMed ID: 18605192
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease.
    Maharshak N; Arbel Y; Gal-Oz A; Rogowski O; Shapira I; Berliner S; Vered Y; Canaani J; Dotan I
    J Dig Dis; 2008 Aug; 9(3):140-3. PubMed ID: 18956591
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical significance of soluble immunoglobulins A and G and their coated bacteria in feces of patients with inflammatory bowel disease.
    Lin R; Chen H; Shu W; Sun M; Fang L; Shi Y; Pang Z; Wu W; Liu Z
    J Transl Med; 2018 Dec; 16(1):359. PubMed ID: 30558634
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.
    Zissimopoulos A; Vradelis S; Konialis M; Chadolias D; Bampali A; Constantinidis T; Efremidou E; Kouklakis G
    Scand J Gastroenterol; 2014 Aug; 49(8):942-9. PubMed ID: 24897131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Food-specific IgGs Are Highly Increased in the Sera of Patients with Inflammatory Bowel Disease and Are Clinically Relevant to the Pathogenesis.
    Xiao N; Liu F; Zhou G; Sun M; Ai F; Liu Z
    Intern Med; 2018 Oct; 57(19):2787-2798. PubMed ID: 29780153
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
    Peeters M; Joossens S; Vermeire S; Vlietinck R; Bossuyt X; Rutgeerts P
    Am J Gastroenterol; 2001 Mar; 96(3):730-4. PubMed ID: 11280542
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity.
    Boga S; Alkim H; Koksal AR; Ozagari AA; Bayram M; Tekin Neijmann S; Sen I; Alkim C
    J Investig Med; 2016 Jun; 64(5):1016-24. PubMed ID: 27001944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serological differentiation of inflammatory bowel diseases.
    Conrad K; Schmechta H; Klafki A; Lobeck G; Uhlig HH; Gerdi S; Henker J
    Eur J Gastroenterol Hepatol; 2002 Feb; 14(2):129-35. PubMed ID: 11981336
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features.
    Annese V; Piepoli A; Perri F; Lombardi G; Latiano A; Napolitano G; Corritore G; Vandewalle P; Poulain D; Colombel JF; Andriulli A
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1143-52. PubMed ID: 15569117
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of intestinal permeability in patients with inflammatory bowel disease using lactulose and measuring antibodies to lipid A.
    Oriishi T; Sata M; Toyonaga A; Sasaki E; Tanikawa K
    Gut; 1995 Jun; 36(6):891-6. PubMed ID: 7615279
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease.
    Degenhardt F; Dirmeier A; Lopez R; Lang S; Kunst C; Roggenbuck D; Reinhold D; Szymczak S; Rogler G; Klebl F; Franke A; Rieder F
    Inflamm Bowel Dis; 2016 Nov; 22(11):2648-2657. PubMed ID: 27753692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum regenerating islet-derived 3-alpha is a biomarker of mucosal enteropathies.
    Marafini I; Di Sabatino A; Zorzi F; Monteleone I; Sedda S; Cupi ML; Antenucci C; Biancheri P; Giuffrida P; Di Stefano M; Corazza GR; Pallone F; Monteleone G
    Aliment Pharmacol Ther; 2014 Oct; 40(8):974-81. PubMed ID: 25112824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Location-based prediction model for Crohn's disease regarding a novel serological marker, anti-chitinase 3-like 1 autoantibodies.
    Sipeki N; Kovats PJ; Deutschmann C; Schierack P; Roggenbuck D; Papp M
    World J Gastroenterol; 2023 Nov; 29(42):5728-5750. PubMed ID: 38075846
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum 25-hydroxyvitamin D concentration and inflammatory bowel disease characteristics in Romania.
    Dumitrescu G; Mihai C; Dranga M; Prelipcean CC
    World J Gastroenterol; 2014 Mar; 20(9):2392-6. PubMed ID: 24605037
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
    Mori A; Mitsuyama K; Sakemi R; Yoshioka S; Fukunaga S; Kuwaki K; Yamauchi R; Araki T; Yoshimura T; Yamasaki H; Tsuruta K; Morita T; Yamasaki S; Tsuruta O; Torimura T
    Kurume Med J; 2021 Dec; 66(4):209-215. PubMed ID: 34690210
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease.
    Karmiris K; Koutroubakis IE; Xidakis C; Polychronaki M; Voudouri T; Kouroumalis EA
    Inflamm Bowel Dis; 2006 Feb; 12(2):100-5. PubMed ID: 16432373
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma Extracellular Vesicle LncRNA H19 as a Potential Diagnostic Biomarker for Inflammatory Bowel Diseases.
    Heydari R; Fayazzadeh S; Shahrokh S; Shekari F; Farsad F; Meyfour A
    Inflamm Bowel Dis; 2024 May; 30(5):795-807. PubMed ID: 37855715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.